ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2024

Mar 21, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2024-03-18

Reporting Person: Lu Hongbo (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-03-18	Common Stock	P	1000	$27.49	Acquired	31680	Direct
2024-03-19	Common Stock	P	1000	$28	Acquired	32680	Direct
2024-03-20	Common Stock	P	1000	$27.50	Acquired	33680	Direct

Footnotes

F1: The price reported on Column 4 is the weighted average price. These shares were purchase in multiple transactions at prices ranging from $ 27.48 to $ 27.50, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.